Logo image of TCBP

TC BIOPHARM HOLDINGS PLC-ADR (TCBP) Stock Fundamental Analysis

NASDAQ:TCBP - Nasdaq - US87807D6085 - ADR - Currency: USD

0.5  -1.04 (-67.53%)

After market: 0.6701 +0.17 (+34.02%)

Fundamental Rating

1

Overall TCBP gets a fundamental rating of 1 out of 10. We evaluated TCBP against 561 industry peers in the Biotechnology industry. Both the profitability and financial health of TCBP have multiple concerns. TCBP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TCBP has reported negative net income.
In the past year TCBP has reported a negative cash flow from operations.
TCBP had negative earnings in each of the past 5 years.
TCBP had a negative operating cash flow in each of the past 5 years.
TCBP Yearly Net Income VS EBIT VS OCF VS FCFTCBP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -5M -10M

1.2 Ratios

TCBP's Return On Assets of -71.77% is on the low side compared to the rest of the industry. TCBP is outperformed by 65.09% of its industry peers.
TCBP has a Return On Equity of -293.88%. This is in the lower half of the industry: TCBP underperforms 73.68% of its industry peers.
Industry RankSector Rank
ROA -71.77%
ROE -293.88%
ROIC N/A
ROA(3y)-82.72%
ROA(5y)-76.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TCBP Yearly ROA, ROE, ROICTCBP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 1K 2K 3K 4K

1.3 Margins

TCBP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TCBP Yearly Profit, Operating, Gross MarginsTCBP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -200 -400 -600

More info and screens

1

2. Health

2.1 Basic Checks

TCBP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TCBP has been increased compared to 1 year ago.
TCBP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TCBP Yearly Shares OutstandingTCBP Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B
TCBP Yearly Total Debt VS Total AssetsTCBP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

TCBP has an Altman-Z score of -8.08. This is a bad value and indicates that TCBP is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -8.08, TCBP is not doing good in the industry: 69.47% of the companies in the same industry are doing better.
TCBP has a Debt/Equity ratio of 1.07. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.07, TCBP is not doing good in the industry: 78.07% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF N/A
Altman-Z -8.08
ROIC/WACCN/A
WACC6.34%
TCBP Yearly LT Debt VS Equity VS FCFTCBP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 -5M -10M -15M

2.3 Liquidity

TCBP has a Current Ratio of 1.09. This is a normal value and indicates that TCBP is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.09, TCBP is doing worse than 87.19% of the companies in the same industry.
TCBP has a Quick Ratio of 1.09. This is a normal value and indicates that TCBP is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.09, TCBP is not doing good in the industry: 85.09% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.09
Quick Ratio 1.09
TCBP Yearly Current Assets VS Current LiabilitesTCBP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

TCBP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -27216.05%.
TCBP shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-27216.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%454.43%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

TCBP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.42% yearly.
The Revenue is expected to decrease by -41.42% on average over the next years. This is quite bad
EPS Next Y96.52%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

TCBP Yearly Revenue VS EstimatesTCBP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 1M 2M 3M
TCBP Yearly EPS VS EstimatesTCBP Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 -10K -20K -30K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TCBP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TCBP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TCBP Price Earnings VS Forward Price EarningsTCBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TCBP Per share dataTCBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as TCBP's earnings are expected to grow with 41.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TCBP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TC BIOPHARM HOLDINGS PLC-ADR

NASDAQ:TCBP (3/21/2025, 8:00:01 PM)

After market: 0.6701 +0.17 (+34.02%)

0.5

-1.04 (-67.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)12-13 2022-12-13/bmo
Inst OwnersN/A
Inst Owner Change-99.68%
Ins OwnersN/A
Ins Owner Change0%
Market Cap5.13M
Analysts82.86
Price Target48.96 (9692%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1500%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-1500%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.97
P/tB 2.81
EV/EBITDA N/A
EPS(TTM)-4.21
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)-1.61
FCFYN/A
OCF(TTM)-1.54
OCFYN/A
SpS0
BVpS0.25
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -71.77%
ROE -293.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-82.72%
ROA(5y)-76.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.09
Quick Ratio 1.09
Altman-Z -8.08
F-Score1
WACC6.34%
ROIC/WACCN/A
Cap/Depr(3y)28.29%
Cap/Depr(5y)69.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-27216.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%454.43%
EPS Next Y96.52%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.79%
OCF growth 3YN/A
OCF growth 5YN/A